Clinical trial
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease…
NCT00247143 · Lampiris, Harry W., M.D., Other · Unknown status
Key facts
| NCT number | NCT00247143 |
|---|---|
| Title | High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease |
| Official title | Prospective Open Label Non-Comparative Study of the Safety, Efficacy and Tolerability of High Dose Ritonavir/Lopinavir Liquid in Salvage Therapy for PI Resistant HIV & a PK Equivalence Sub-Study of High Dose Ritonavir/Lopinavir Capsules |
| Lead sponsor | Lampiris, Harry W., M.D., Other |
| Collaborators | Abbott Industry |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | HIV, AIDS |
| Intervention type | Drug |
| Interventions | Kaletra (drug) |
| Enrollment | 20 |
| Start date | Oct 1, 2005 |
| First posted | Nov 1, 2005 |
| Last update posted | Sep 20, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: